Adeona’s Experimental RA Drug Does Well in Phase II Trial

Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.

Read more »

Positive Rheumatoid Arthritis Data for UCB, Trubion, Others

Data presented this weekend at the American College of Rheumatology’s annual meeting indicated that rheumatoid arthritis patients who adhered to a prescription drug regimen had better medical outcomes and lower medical costs.

Read more »